Today's guest post is by Pete Salzmann, VP, Immunology at Lilly.
During my training as a physician at the University of California, San Francisco, I often worked with patients facing conditions that were difficult to diagnose and challenging to treat. At the time – the mid-1990s -- remission was particularly elusive for people with rheumatic diseases such as rheumatoid arthritis (RA).
The good news is that advances in treatment have made remission possible for many patients. But we still have far to go. Too many people with RA and other conditions continue to suffer in silence and can’t sustain remission, despite the many treatment options available that weren’t around 25 years ago.
The potential to bring new innovations to help providers tailor their treatment plans and help even more patients is incredibly motivating. It’s why I love my job. And why I’m energized heading to the American College of Rheumatology and Association of Rheumatology Health Professional’s (ACR/ARHP) annual meeting this week in San Diego, where the world’s leading rheumatology experts will come together to share the latest research on treatment advances.
San Diego is also home to Lilly’s biotechnology research facility, where our scientists work tirelessly to help people who live with some of the most debilitating diseases imaginable.
And that’s exactly who the dedicated professionals at this meeting are here to serve.
Each year at ACR/ARHP, we hear remarkable findings on more than 100 diseases in rheumatology including rheumatoid arthritis, psoriasis, psoriatic arthritis, atopic dermatitis, osteoporosis and lupus. The data presented in these sessions always reminds me of the vital importance of ongoing research and innovation in this space. Of course, forging new frontiers in immunology is no simple task in scope or scale.
That’s why we are pushing forward at Lilly. Serving the patients with the most difficult conditions in immunology is especially important to me.
As a company, Lilly is committed to bringing innovation to patients suffering from complex conditions with incomplete remedies. By focusing on key pathways and interventions based on antibodies, traditional oral new chemical entities, and novel biologics, we will power our potential. So, I’m eager to see the progress since last year’s ACR, and I’m excited for a hopeful future for people with immunological diseases.